1Garbett EA, Reed MW, Brown NJ, et al. Proteolysis in human breast and colorectal cancer[J]. Br J Cancer, 1999, 81(2) :287-293
2Davies B, Waxman J, Wasan H, et al. Levels of Matrix metalloproteinases in bladder cancer correlate with tumor grade and invasion[J]. Cancer Res, 1993,53(22) :5 365-5 369
3Monteagudo C, Merino MJ, San JJ, et al. Immunohistochemical distribution of type IV collagenase in normal, benign, and malignant breast tissue[J]. J Pathol, 1990,136(3):585-592
4Levy AT, Cioce V, Sobel ME, et al. Increased expression of the Mr 72000 type IV collagenase in human colonic adenocarcinoma[J]. Cancer Res, 1991,51(1):439-444
6Furukawa A, Tsuji M, Nishitani M, et al. Role of the matrix metalloproteinase and tissue inhibitors of metalloproteinase families in noninvasive and invasive tumors transplanted in mice with severe combined immunodeficiency[M]. Urology,1998,51:849-853
7Sehgal G, Hua J, Bernhard EJ. Requirement for matrix metalloproteinase-9 (gelatinase B) expression in metastasis by murine prostate carcinoma[M]. Am J Pathol, 1998,152:591-596
8DeClerk YA, Yeah TD, Chan D, et al. Inhibition of tumor invasion of smooth muscle cell layers by recombinant human metalloproteinase inhibitor[J]. Cancer Res, 1991,51 (8): 2151-2 57
9Schnaper HW, Grant DS, Stetler-Stevenson WG, et al. Type IV collagenase and TIMPs modulate endothelial cell morphogenesis in vitro[M]. J Cell Physiol, 1993,156:235-246
10Fang J, shing Y, Wiederschain D, et al. Matrix metalloproteinase-2 is required for the switch to angiogenic phenotype in tumor model[J]. Proc Natl Acad Sci USA, 2000,97(8):3884-3889
